Results 71 to 80 of about 13,388,853 (301)

DPP-4 activity affected by the presence of Myr and HP (μmol/mg/min).

, 2020
DPP-4 activity affected by the presence of Myr and HP (μmol/mg/min).
Talahalli Ravichandra Ramaprasad (8703693), Bettadahalli Sadashivaiah (8703690), Nanjaiah Lalitha (8703687), Sridevi Annapurna Singh (8703696)   +3 more
core   +1 more source

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure [PDF]

, 2011
Background Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half ...
Rudolf A de Boer, Maxi Meissner, van Gilst Wiek H, Wiek H van Gilst, de Boer, Rudolf A., Yin Meimei, de Boer Rudolf A, Sillje, Herman H. W., van Gilst, Wiek H., Meimei Yin, Meissner Maxi, Silljé Herman HW, Yin, Meimei, Herman HW Silljé, Meissner, Maxi   +14 more
core   +2 more sources

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Time course of the recovery of DPP-4 activity following dissociation of trelagliptin from the preformed DPP-4-inhibitor complex.

, 2016
A preformed enzyme-inhibitor complex (where [DPP-4] = 50 nmol/L and trelagliptin concentration is as shown in the plot) was diluted 50-fold into a solution containing 2 mmol/L GP-pNA substrate (approximately 17x Km).
Yoshinobu Kinugawa (3165234), Nobuhiro Nishigaki (2134261), Akiyoshi Tani (2231677), Hiroki Sano (2962497), Koji Takeuchi (469159), Charles E. Grimshaw (3165231), Andy Jennings (2235538), Hikaru Ueno (3165237), Takuo Kosaka (2231683), Lihong Shi (481066), Emiko Koumura (3165240), Ruhi Kamran (1786588)   +11 more
core   +1 more source

Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. [PDF]

, 2012
Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the
Rauch, Thomas, Heise, Tim, Holst, Jens Juul, Graefe-Mody, U, Dugi, Klaus A, Rauch, T, Ring, A, Dugi, KA, Graefe-Mody, Ulrike, Deacon, Carolyn F., Heise, T, Deacon, Carolyn F, Ring, Arne, Woerle, Hans-Juergen, Woerle, H-J   +14 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

, 2013
Miyako KishimotoDepartment of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, JapanAbstract: Dipeptidyl peptidase-
Kishimoto M
core  

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source